Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.46 |
| ▸ | VEGFA | P15692 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8686933 | 0.96 | SLC6A4 (0.53) | SLC6A4MEN1KMT2A | |
| SCHEMBL6174995 | 0.85 | SPHK2 (0.48) | SLC6A4SPHK2SPHK1FAAH | |
| SCHEMBL1903624 | 0.85 | SPHK2 (0.48) | SLC6A4SPHK2SPHK1FAAH | |
| SCHEMBL11199979 | 0.81 | SPHK2 (0.50) | SPHK2SPHK1VEGFAEGLN1FAAH | |
| SCHEMBL1257677 | 0.81 | SLC6A4 (0.49) | SLC6A4SPHK2SPHK1 | |
| SCHEMBL1257675 | 0.81 | SLC6A4 (0.49) | SLC6A4SPHK2SPHK1 | |
| SCHEMBL24200095 | 0.80 | SPHK2 (0.49) | SPHK2SPHK1VEGFAEGLN1FAAH | |
| SCHEMBL16416519 | 0.80 | VEGFA (0.64) | SPHK2SPHK1VEGFAEGLN1 | |
| SCHEMBL11199921 | 0.79 | SPHK2 (0.51) | SPHK2SPHK1FAAH | |
| SCHEMBL5530480 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | SLC6A4 2731/4885SPHK2 1400/4885SPHK1 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.